Chair: Peter Gunter
Co-Chairs: Durwin Day Chris Johnson
Scribe: Robin Isgett
Antitrust Statement
Professional Associations, such as HL7, which bring together competing entities are subject to strict
scrutiny under applicable antitrust laws. HL7 recognizes that the antitrust laws were enacted to promote
fairness in competition and, as such, supports laws against monopoly and restraints of trade and their
enforcement. Each individual participating in HL7 meetings and conferences, regardless of venue, is
responsible for knowing the contents of and adhering to the HL7 Antitrust Policy as stated in §05.01 of
the Governance and Operations Manual (GOM).
NOTE: This attendance applies if you are present at the related meeting/call, regardless if you have signed a different attendance for your WG.
Attendees
Present | Name | Affiliation |
|---|---|---|
@username | ||
| x | ||
| x | ||
| x | ||
| x | ||
| x | ||
| x | ||
| x | ||
| x | Prabal Basu |
Minutes Approved as Presented
This is to approve minutes via general consent. "You have received the minutes. Are there any corrections to the minutes? (pause) Hearing none, if there are no objections, the minutes are approved as printed."
Agenda Topics
Agenda Outline | Agenda Item | Meeting Minutes from Discussion | Decision Link(if not child) |
|---|---|---|---|
Antitrust StatementProfessional Associations, such as HL7, which bring together competing entities are subject to strict | Peter read Antitrust reminder. | ||
| Management | Minutes Approval | Corrected NCVHS spelling and approved minutes by consensus. | |
| Management | New Proposals and PSS for review - PIE comments or interest | 2137 - Pharmaceutical Quality Creation and exchange, CMC is for Chemistry, Manufacturing and Controls. Commented that PIE WG was not an interested party. 2127 - FHIR Eligibility for Clinical Trials Biomedical Research and Regulation is the sponsor. Commented that the PIE WG is an interested party because we want to ensure that SDOH are included in eligibility criteria. | |
| Management | Updates: MnM Dissolution/Merger with FHIR-I TSC Consideration of the Request Last week TSC to take up the request to merge MnM with FHIR-I, dissolve MnM, and update the FHIR-I Mission and Charter to cover FHIR Methodology ▪ TSC members were asked to consider the comments submitted by work groups as part of the Work Group vote before casting their own votes on “merger” of MnM with FHIR-I ▪ After considerable discussion (including about the work group comments), the TSC voted to approve the merger request - This includes the dissolution of MnM, and the updated Mission and Charter for FHIR-I - Please see the TSC minutes for that discussion https://confluence.hl7.org/pages/viewpage.action?pageId=144972394 ▪ At this point, there is no work group directly responsible for Version 3 Methodology - If substantial questions about V3 methodology arise, the TSC would need to convene a group of remaining V3 experts to address such questions | Reviewed update. | |
| Management | NCVHS Request for Comment (RFC) in advance of the body’s scheduled January 18-19, 2023 full meeting. Click here for the template - Call for Comments - NCVHS X12 and CAQH CORE Proposals Last week we covered the first 5 - X12 Claims/Remit questions and drafted responses. We will roll to next weeks meeting and begin a #6. This document can be located in PIE Documentation/Presentations: | #6 APM & VBP Alternative Payment Models and Value Based Purchasing Could not verify if 8020 supports VBP on the call. Claims support the use of diagnosis codes and procedure codes that are used in VBP. Additional information can be accommodated in a claim as necessary. #7 Implementation Time Frame
| NCVHS RFC - Comment Template - November 7 FINAL 11 22 2022 _1529.docx |
| Open Floor | No discussion. | ||
| Adjournment | Adjourned at 3:28 PM EST |
Supporting Documents
Outline Reference | Supporting Document |
|---|---|
| Minute Approval | |